Shots:
- CivicaScript has reported that Insulin Glargine-yfgn and Ustekinumab-aauz, biosimilar versions of Lantus and Stelara, are now available in the US
- Civica insulin glargine-yfgn is an interchangeable Lantus® insulin for adults and children with diabetes, developed through a Civica-led collaboration. It is marketed nationally by CivicaScript and branded as CalRx in California through the state’s CalRx program
- Ustekinumab-aauz is an IL-12/23 antagonist indicated for select patients with plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, and is interchangeable with the reference product Stelara (ustekinumab)
Ref: CivicaScript | Image: CivicaScript | Press Release
Related News: CivicaScript is set to distribute Ustekinumab-aauz (Biosimilar, Stelara) for Chronic Inflammatory Conditions
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
